Table 1 Aggregated costs of tests, staging, inpatient, medication, follow-up, screening, complications and end-of-life (index year 2017)
From: Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria
Item | Costs at index year 2017, EUR |
|---|---|
Costs for tests | |
Colonoscopy | 228 |
Polypectomy | 64 |
gFOBT (gFOBT stool test only) | 37 (0.83) |
FIT (FIT stool test only) | 41 (0.89) |
Staging costs (weighted mean of colorectal cancer and rectal cancer) | 461 |
Aggregated inpatient-care costs (weighted mean of colorectal cancer and rectal cancer at UICC level) | |
UICC I | 13,831 |
UICC II | 18,699 |
Costs UICC III | 19,038 |
Costs UICC IV | 24,059 |
Aggregated medication costs (UICC IV) | 12,433 |
Aggregated follow-up costs (weighted mean of colorectal cancer and rectal cancer separately for follow-up year, including medical consultation, tumor marker laboratory, colonoscopy/rectoscopy, CT) | |
Costs: Year 1 | 552 |
Costs: Year 2 | 367 |
Costs: Year 3 | 349 |
Costs: Year 4 | 419 |
Costs: Year 5 | 237 |
Costs: Year 9, 14, lifelong every 60 months | 228 |
Costs for screening program | |
Colonoscopy screening program (10-yearly) | 1,950,353 |
Stool-based screening program (annually) | 4,118,142 |
Costs of complications (inpatient stay) | |
Surgical procedures | 23,258 |
Inpatient stay | 5250 |
End-of-life costs (inpatient care + medication) | |
One-time costs, cancer death at UICC I and UICC II | 55,530 |
One-time costs, cancer death at UICC III | 36,492 |